| Date | Title | Description | Source |
| 01.04.2024 | Rhythm Pharmaceuticals Secures $150 Million in Convertible P... | - | globenewsw... |
| 11.03.2024 | Rhythm Pharmaceuticals Announces New Employment Inducement G... | - | globenewsw... |
| 11.03.2024 | Rhythm Pharmaceuticals Announces New Employment Inducement G... | BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial... | einpresswi... |
| 06.03.2024 | Rhythm Pharmaceuticals Announces Participation at Upcoming I... | - | globenewsw... |
| 06.03.2023 | Rhythm Pharmaceuticals Acquires Xinvento | Rhythm Pharmaceuticals, a Boston, MA-based commercial-stage biopharmaceutical company, acquired Xinv... | finsmes.co... |
| 03.11.2022 | Rhythm Pharmaceuticals Announces 11 Presentations at The Obe... | /EIN News/ -- -- Analyses of Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) in child... | einpresswi... |
| 19.09.2022 | Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Mil... | BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a... | globenewsw... |
| 12.07.2022 | Jubilant HollisterStier pumps $77M into Montreal fa... | Verve Therapeutics has dosed the first patient with its lead cardiovascular drug, marking a major mi... | endpts.com... |
| 12.07.2022 | Jubilant HollisterStier pumps $77M into Montreal fa... | Following a second FDA OK for its genetic obesity drug last month for patients with Bardet-Biedl syn... | endpts.com... |
| 12.07.2022 | 'Approvability has been put to bed': Aldeyra says eye dr... | Aldeyra’s attempt at treating dry eye disease has seen a few ups and downs in recent years, but ... | endpts.com... |
| 12.07.2022 | Flagship unwraps new AI biotech that looks to predict var... | While Moderna is testing Omicron-specific boosters for this fall, its investor Flagship Pi... | endpts.com... |
| 13.01.2022 | Camurus announces dosing initiated in Phase 3 trial of weekl... | Lund, Sweden - 13 January 2022 - Camurus (NASDAQ STO: CAMX) today announces that the company's licen... | marketscre... |
| 13.01.2022 | Camurus announces dosing initiated in Phase 3 trial of weekl... | Camurus announces dosing initiated in Phase 3 trial of weekly setmelanotide in patients with genetic... | news.cisio... |
| 02.11.2021 | Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial ... | Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
-- U.S. and EU regulatory filing... | marketscre... |
| 02.11.2021 | Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial ... | -- U.S. and EU regulatory filings submitted for IMCIVREE® (setmelanotide) for treatment of Bardet-Bi... | marketscre... |
| 14.10.2021 | Rhythm Pharmaceuticals : Presents New Data on Experience of ... | -- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically me... | marketscre... |
| 22.09.2021 | Rhythm Pharmaceuticals : Presents New Data from Phase 2 and ... | -- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weigh... | marketscre... |
| 03.08.2021 | Rhythm Pharmaceuticals : Announces Comprehensive Expansion o... | -- Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1... | marketscre... |
| 10.02.2021 | Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Mil... | BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmace... | globenewsw... |
| 07.01.2020 | Rhythm CEO Keith Gottesdiener hits the exit; Takeda set... | → Rhythm Pharmaceuticals $RYTM CEO Keith Gottesdiener is planning to stay at the helm until... | endpts.com... |
| 08.11.2019 | With key test still looming, Celgene and Acceleron nab FD... | While pricing concerns continue to cloud the future of bluebird bio’s gene therapy fix, the ... | endpts.com... |
| 10.11.2017 | Novartis makes its case on why RTH258 can grab a blockbus... | Vasant Narasimhan, Novartis’ CEO-designate Bloomberg
Soon-to-be Novartis $NVS CEO Vas Narasim... | endpts.com... |
| 06.10.2017 | Term Sheet — Friday, October 6 | DAYS OF CHANGE
Happy Friday, Term Sheet readers.
Paid Content You can't secure what you can't see Fr... | fortune.co... |
| 06.09.2017 | Term Sheet — Wednesday, September 6 | SHOPPING SPREE
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cy... | fortune.co... |
| 24.08.2017 | AstraZeneca researchers plumb positive data to back ex... | After suffering back-to-back clinical failures last year that forced AstraZeneca to finally... | endpts.com... |
| 17.02.2017 | NEA Leads $41M Round For Rhythm | Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies th... | citybizlis... |
| 17.02.2017 | Term Sheet — Friday, February 17 | IT’s TIME TO TAKE AI SERIOUSLY
The following is from the latest print edition of Fortune, where I wr... | fortune.co... |
| 16.02.2017 | Rhythm Completes $41 Million Mezzanine Financing | Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic deficiencies th... | citybizlis... |
| 16.02.2017 | Rhythm Closes $41M Mezzanine Financing | Rhythm, a Boston, MA-based biopharmaceutical company developing peptide therapeutics for rare geneti... | finsmes.co... |
| 07.07.2016 | KaloBios binds up Martin Shkreli and cages his stock in a... | The new CEO at KaloBios has already made it clear that he doesn’t want to see Martin Shkreli pla... | endpts.com... |
| 13.08.2015 | Rhythm Completes $40M Series A Financing | Rhythm, a Boston, Massachusetts-based biopharmaceutical company developing peptide therapeutics that... | finsmes.co... |
| 13.08.2015 | Daily funding roundup - August 13, 2015 | Massdrop landed $40M; View raised $150M; DispatchHealth secured $3.6M
Massdrop raised a $40 million ... | vator.tv/n... |
| 28.08.2014 | Rhythm Files for IPO | Rhythm, a Boston, Mass.-based biopharmaceutical company developing peptide therapeutics that address... | finsmes.co... |
| 27.11.2012 | Rhythm Closes Additional $8M in Series B Financing | Rhythm, a Boston, MA-based biotechnology company, has closed on an additional $8m in Series B financ... | finsmes.co... |
| 13.06.2012 | Rhythm Raises $25M in Series B Financing | Rhythm, a Boston, Massachusetts-based biotechnology company developing peptide therapeutics that add... | finsmes.co... |
| 15.09.2010 | Third Rock raises $426 million, opens in San Fran | Boston investment firm Third Rock Ventures LLC has raised $426 million for its second (oversubscribe... | massdevice... |
| 14.09.2010 | Third Rock Ventures raises $426M, opens West Coast office | Founded in 2007 with a $378 million fund, Third Rock has invested in 15 life sciences companies, inc... | medcitynew... |
| 08.09.2010 | Rhythm Completes $40M Series A Financing Round | Rhythm, a Boston, Massachusetts-based biotechnology company developing peptide therapeutics for meta... | finsmes.co... |
| 29.03.2010 | Morning Read: VC dollars are chasing obesity | Boston-based Rhythm Pharmaceuticals, which raised $21 million in a Series A round for treatments for... | medcitynew... |
| - | Morning Read: VC dollars are chasing obesity | Highlights of the important and the interesting from the world of healthcare:
VC dollars are chasing... | medcitynew... |
| - | Third Rock Ventures raises $426M, opens West Coast office | Boston investment firm Third Rock Ventures LLC has raised $426 million for its second (oversubscribe... | medcitynew... |
